▶ Manufacturer: Ilhwa Co., Ltd.
▶ Sold by: Ilhwa Co., Ltd.
▶ Insurance code : 640902810
▶ Storage : Airtight container, room temperature (1~30℃)
This item has been added to your cart.
Reddish-brown circular film-coated tablet
Amlodipine besylate 6.944mg (5mg as amlodipine), Olmesartan medoxomil 40mg
One tablet is to be administered once a day. Administration at the same time daily (e.g. morning) is recommended. Whereas adjusting doses of individual substances (Amlodipine or Olmesartan Medoxomil) is recommended prior to administering this drug, switching directly to this drug may be considered if blood pressure cannot be regulated through single therapy using individual substances.
Max. administration dose for this drug is 10/40mg. As the maximum hypotensive effect is exhibited within 2 weeks of administration, adjust dose at intervals of 2 weeks or longer, with consideration for the patient’s blood pressure response.
Recommended administration doses are as follow.
- 5/20mg: Administer to patients whose blood pressure is not appropriately regulated by single therapy of 5mg Amlodipine or 20mg Olmesartan Medoxomil.
- 10/20mg: Administer to patients whose blood pressure is not appropriately regulated by single therapy of 20mg Olmesartan Medoxomil.
- 5/40mg: Administer to patients whose blood pressure is not appropriately regulated by 5/20mg.
- 10/40mg : Administer to patients whose blood pressure is not appropriately regulated by 5/40mg.
Renal impairment patients: No studies done using this drug on patients with renal impairment. However, max. administration dose of Olmesartan Medoxomil for patients with mild to moderately severe renal failure (creatinine clearance 20 to 60mL/min) is 20mg once a day, and administration of this drug is not recommended for patients with moderately severe to severe renal impairment (e.g. creatinine clearance < 20mL/min) and patients undergoing dialysis. For moderately severe renal failure patients, monitoring of potassium and creatinine levels is recommended.
Patients with intravascular volume depletion: For patients with a possibility of intravascular volume depletion (e.g. patients taking diuretics, esp. patients with renal impairment), starting administration at low doses while sufficiently observing patient status is recommended.
Liver impairment patients: Proceed with caution when administering to mild to moderately severe liver impairment patients. Recommended initial dose for moderately severe liver impairment patients is 10mg Olmesartan Medoxomil once a day, and max. administration dose is 20mg once a day. Among patients having already been administered other anti-hypertension drugs and/or diuretics, blood pressure and renal function must be closely monitored for patients with liver impairment. This drug should not be administered to patients with severely damaged liver function. (See Precautions for Use, 2. Do not administer to the following patients)
Elderly patients: Generally begin administration at low doses, and consider patient’s renal function, cardiac function, and diseases when adjusting dose. For elderly patients, closer and more frequent monitoring of blood pressure is necessary.
Pediatrics: Safety and efficacy not established for pediatric patients under 18 years of age.
Treatment of essential hypertension where blood pressure is not appropriately regulated by single therapy of Amlodipine or Olmesartan Medoxomil.
Reddish-brown circular film-coated tablet
Amlodipine besylate 6.944mg (5mg as amlodipine), Olmesartan medoxomil 40mg
One tablet is to be administered once a day. Administration at the same time daily (e.g. morning) is recommended. Whereas adjusting doses of individual substances (Amlodipine or Olmesartan Medoxomil) is recommended prior to administering this drug, switching directly to this drug may be considered if blood pressure cannot be regulated through single therapy using individual substances.
Max. administration dose for this drug is 10/40mg. As the maximum hypotensive effect is exhibited within 2 weeks of administration, adjust dose at intervals of 2 weeks or longer, with consideration for the patient’s blood pressure response.
Recommended administration doses are as follow.
- 5/20mg: Administer to patients whose blood pressure is not appropriately regulated by single therapy of 5mg Amlodipine or 20mg Olmesartan Medoxomil.
- 10/20mg: Administer to patients whose blood pressure is not appropriately regulated by single therapy of 20mg Olmesartan Medoxomil.
- 5/40mg: Administer to patients whose blood pressure is not appropriately regulated by 5/20mg.
- 10/40mg : Administer to patients whose blood pressure is not appropriately regulated by 5/40mg.
Renal impairment patients: No studies done using this drug on patients with renal impairment. However, max. administration dose of Olmesartan Medoxomil for patients with mild to moderately severe renal failure (creatinine clearance 20 to 60mL/min) is 20mg once a day, and administration of this drug is not recommended for patients with moderately severe to severe renal impairment (e.g. creatinine clearance < 20mL/min) and patients undergoing dialysis. For moderately severe renal failure patients, monitoring of potassium and creatinine levels is recommended.
Patients with intravascular volume depletion: For patients with a possibility of intravascular volume depletion (e.g. patients taking diuretics, esp. patients with renal impairment), starting administration at low doses while sufficiently observing patient status is recommended.
Liver impairment patients: Proceed with caution when administering to mild to moderately severe liver impairment patients. Recommended initial dose for moderately severe liver impairment patients is 10mg Olmesartan Medoxomil once a day, and max. administration dose is 20mg once a day. Among patients having already been administered other anti-hypertension drugs and/or diuretics, blood pressure and renal function must be closely monitored for patients with liver impairment. This drug should not be administered to patients with severely damaged liver function. (See Precautions for Use, 2. Do not administer to the following patients)
Elderly patients: Generally begin administration at low doses, and consider patient’s renal function, cardiac function, and diseases when adjusting dose. For elderly patients, closer and more frequent monitoring of blood pressure is necessary.
Pediatrics: Safety and efficacy not established for pediatric patients under 18 years of age.
Treatment of essential hypertension where blood pressure is not appropriately regulated by single therapy of Amlodipine or Olmesartan Medoxomil.